Vertex Pharmaceuticals Inc (VRTX) Institutional Ownership Tracker (Q2 2026)

VRTX ranks #179 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1771 institutions disclose a position in VRTX, but none treat it as a major bet — even Loomis Sayles & Co L P, its most concentrated holder, allocates just 2.4% of its own portfolio to it.

Invesco Ltd. has added to its VRTX position for two straight quarters, increasing it by $3.0B to reach $4.0B today.

Alliancebernstein L.p. has trimmed its VRTX position for two straight quarters, cutting it by $690.3M while still holding $1.3B.

VRTX is up 1% today, and institutions have been net buyers of $56.6B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VRTX posted net income of $4.4B over the trailing twelve months, and currently trades at a P/E of 32.4.

• Profitable — net income of $4.4B over the trailing twelve months
• Revenue grew 10.2% year over year
• Net income improved year over year, from $3.6B to $4.4B
• Generated $3.6B in positive operating cash flow
• Current ratio of 2.90x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.37x equity — within a conventional range